Calidi Biotherapeutics and City of Hope Report the First Patient Dosing of CLD-101 in the P-I Trial for Recurrent High-Grade Glioma
Shots:
- The first patient has been dosed at City of Hope in the P-I trial evaluating CLD-101. The trial focuses to identify the safety, immunogenicity, preliminary clinical efficacy & multiple intracerebral doses of CLD-101
- The P-I dose escalation trial results showed that CLD-101 as an adjunct to standard radiation & temozolomide was well-tolerated and demonstrated safety along with stimulation of an anti-tumor immune response. Calidi plans to sponsor a P-Ib/II trial to advance CLD-101 in newly diagnosed glioma
- CLD-101, a leading-edge therapeutic candidate in the NeuroNova program comprising tumor-tropic NSCs delivers an oncolytic adenovirus CRAd-S-pk7 selectively to tumor sites. Calidi retains an exclusive license globally for patents covering NSC-CRAd-S-pk7 for its CLD-101 technology
Ref: Calidi | Image: Calidi
Related News:- Oblato Reports the First Patient Enrolment of OKN-007 in the P-I Clinical Trial for Recurrent High-Grade Glioma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
